Clinical networks are increasingly integrating whole-genome sequencing into routine oncology diagnostics. By analyzing specific genetic mutations at initial screening, medical teams can deploy targeted therapies faster and with greater precision.
Clinical Outcomes and Cost Reduction
Early clinical trial results demonstrate a 22% improvement in treatment response rates among patients receiving biomarker-matched therapies. Furthermore, targeted intervention reduces unnecessary broader treatments, lowering long-term hospital admission costs.